Statements (38)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
prostacyclin analogue |
| gptkbp:approvalYear |
2002
|
| gptkbp:ATCCode |
B01AC21
|
| gptkbp:brand |
gptkb:Orenitram
gptkb:Remodulin gptkb:Tyvaso |
| gptkbp:CASNumber |
81846-19-7
|
| gptkbp:chemicalFormula |
C23H34O5
|
| gptkbp:contraindication |
severe liver impairment
|
| gptkbp:developer |
gptkb:United_Therapeutics
|
| gptkbp:drugClass |
vasodilator
|
| gptkbp:eliminationHalfLife |
4 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
treprostinil
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
vasodilation
inhibition of platelet aggregation |
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
390.51 g/mol
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
subcutaneous inhalation intravenous |
| gptkbp:sideEffect |
nausea
diarrhea headache flushing pain at infusion site |
| gptkbp:status |
FDA approved
|
| gptkbp:synonym |
UT-15
|
| gptkbp:usedFor |
pulmonary arterial hypertension
|
| gptkbp:bfsParent |
gptkb:Lyumjev
gptkb:Orenitram gptkb:Remodulin gptkb:Tyvaso gptkb:LIQ861 |
| gptkbp:bfsLayer |
8
|